Who are Kalaris Therapeutics, Inc.'s main suppliers?

Kalaris Therapeutics, Inc. (KLRS) key suppliers include: KBI-BIOPHARMA, SHARP-STERILE-MANUFACTURING, STC-BIOLOGICS-INC, UCSD, 4D Molecular Therapeutics, Inc. and 4 more. View the full supplier network at chainsifter.com/chain/KLRS.

Who are Kalaris Therapeutics, Inc.'s major customers?

Kalaris Therapeutics, Inc. (KLRS) key customers include: 4D Molecular Therapeutics, Inc., 4D Molecular Therapeutics, Inc., Eli Lilly and Company, Eli Lilly and Company, Novartis AG and 12 more. View the full customer network at chainsifter.com/chain/KLRS.

What sector is Kalaris Therapeutics, Inc. in?

Kalaris Therapeutics, Inc. (KLRS) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Kalaris Therapeutics, Inc. Suppliers, Customers & Supply Chain (KLRS)

9Suppliers

17Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Kalaris Therapeutics, Inc. (KLRS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

28Total relationships

3Distinct source URLs

6High confidence

0.741Average confidence

2026-10-29Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Kalaris Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
KBI-BIOPHARMA	KBI-BIOPHARMA	90%	Additionally, KBI Biopharma, based in North Carolina, is our Contract Development and Manufacturing Organization ("CDMO") for future clinical and commercial supply manufacturing of TH103 drug substance.
SHARP-STERILE-MANUFACTURING	SHARP-STERILE-MANUFACTURING	90%	Our principal contract manufacturers are STC Biologics, Inc. and Sharp Sterile Manufacturing (formerly, Berkshire Sterile Manufacturing Inc.).
STC-BIOLOGICS-INC	STC-BIOLOGICS-INC	90%	Our principal contract manufacturers are STC Biologics, Inc. and Sharp Sterile Manufacturing (formerly, Berkshire Sterile Manufacturing Inc.).
UCSD	UCSD	90%	Under the UCSD Agreement, the Company is required to make annual license maintenance payments of $ 10,000 during the first four anniversaries and $ 15,000 on the fifth and every subsequent anniversar…
FDMT	4D Molecular Therapeutics, Inc.	72%	Reciprocal relationship from FDMT graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from FDMT g…
NVSEF	Novartis AG	72%	Reciprocal relationship from NVSEF graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from NVSE…
OCUL	Ocular Therapeutix, Inc.	72%	Reciprocal relationship from OCUL graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from OCUL graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from OCUL g…
OTLK	Outlook Therapeutics, Inc.	72%	Reciprocal relationship from OTLK graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from OTLK graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from OTLK g…
REGN	Regeneron Pharmaceuticals, Inc.	72%	Reciprocal relationship from REGN graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from REGN graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from REGN g…

Kalaris Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
FDMT	4D Molecular Therapeutics, Inc.	72%	or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, with our own specialty salesforce. There are risks involved with us establishing our…
FDMT	4D Molecular Therapeutics, Inc.	72%	Reciprocal relationship from FDMT graph: Reciprocal relationship from KLRS graph: or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, wi…
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from KLRS graph: es or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, …
LLY	Eli Lilly and Company	72%	es or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, with our own specialty salesforce. There are risks involved with us establishing …
NVSEF	Novartis AG	72%	Reciprocal relationship from NVSEF graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from KLRS graph: Reciprocal relationship from NVSE…
NVSEF	Novartis AG	72%	or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, with our own specialty salesforce. There are risks involved with us establishing our…
OCUL	Ocular Therapeutix, Inc.	72%	or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, with our own specialty salesforce. There are risks involved with us establishing our…
OCUL	Ocular Therapeutix, Inc.	72%	Reciprocal relationship from OCUL graph: Reciprocal relationship from KLRS graph: or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, wi…
OTLK	Outlook Therapeutics, Inc.	72%	Reciprocal relationship from OTLK graph: Reciprocal relationship from KLRS graph: or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, wi…
OTLK	Outlook Therapeutics, Inc.	72%	or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, with our own specialty salesforce. There are risks involved with us establishing our…
REGN	Regeneron Pharmaceuticals, Inc.	72%	or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, with our own specialty salesforce. There are risks involved with us establishing our…
REGN	Regeneron Pharmaceuticals, Inc.	72%	Reciprocal relationship from REGN graph: Reciprocal relationship from KLRS graph: or through collaborations or other arrangements with third parties. We intend to commercialize TH103, if approved, wi…
ADCYTE-LLC	ADCYTE-LLC	62%	debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, the State of Washington passed the My Heal…
CHEVRON-U-S-A-INC	CHEVRON-U-S-A-INC	62%	rotected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. We intend to use registered or unregistered trademarks or trade name…
CORNER-POST-INC	CORNER-POST-INC	62%	rotected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. We intend to use registered or unregistered trademarks or trade name…
NATURAL-RESOURCES-DEFENSE-COUNCIL-INC	NATURAL-RESOURCES-DEFENSE-COUNCIL-INC	62%	rotected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. We intend to use registered or unregistered trademarks or trade name…
VIRACYTE-LLC	VIRACYTE-LLC	62%	debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, the State of Washington passed the My Heal…

Kalaris Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
KLRS-DEBT-10529	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.

Kalaris Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Kalaris Therapeutics, Inc..

Kalaris Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
KLRS-OWNER-SAMSARA-BIOCAPITAL-LLC	SAMSARA BIOCAPITAL, LLC	90%	13F overlay lists SAMSARA BIOCAPITAL, LLC as top holder; 58 tracked holders.

Kalaris Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
ALEC	Alector, Inc.	100.00	2
NVO	Novo Nordisk A/S	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	1	['customer', 'supplier']
SDGR	Schrödinger, Inc.	100.00	2
SLGL	Sol-Gel Technologies Ltd.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
FHTX	Foghorn Therapeutics Inc.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
AKTS	Aktis Oncology, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
BYSI	BeyondSpring Inc.	100.00	2

Kalaris Therapeutics, Inc. Supply Chain